ARIANNA ® is a drug based on ethinyl estradiol + gestodene
THERAPEUTIC GROUP: Systemic hormonal contraceptives - Progestin and estrogens, fixed combination
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications ARIANNA ® - Contraceptive Pill
ARIANNA ® is used as an oral contraceptive.
Mechanism of Action ARIANNA ® - Contraceptive Pill
ARIANNA ® is a third generation oral contraceptive, given the presence of a synthetic progestogen such as gestodene.
Despite the presence of synthetic progestins, which are essentially useful for controlling some of the most common side effects of oral contraception such as water retention, weight gain and skin disorders, third generation contraceptives perform the contraceptive effect in a similar way to how much made from classic contraceptives.
In fact, the inhibition of ovulation induced by the negative feedback exerted on the hypothalamus in relation to the secretion of gonadotropins, and the chemical-physical variations induced at the level of the cervical mucus necessary to counteract the rise of the spermatozoa in the female genital tract, represent the main mechanisms through which ethinylestradiol and gestodene contained in ARIANNA ® guarantee the contraceptive effect.
The long half-life of both active ingredients, estimated at around 24 hours, also allows the preservation of the anti-conventional action by simply taking one tablet a day, preferably always at the same time.
Studies carried out and clinical efficacy
1. THIRD GENERATION AND CARIDARY FREQUENCY CONTRACTS
Interesting study that demonstrates how the administration of oral contraceptives based on ethinyl estradiol and gestodene does not affect heart rate in any way, thus not minimally affecting the rhythmic properties of the heart.
2. CONTRAFFECTIVES BASED ON MANAGERS AND ATHLETIC CAPACITIES
Study that comforts all the athletes subjected to combined hormonal contraception. In fact, the work demonstrates how the intake of ethinyl estradiol-based hormonal contraceptives and gestodene not prolonging aerobic capacity, let alone the maximum force peak, for prolonged periods.
3. CONTRACEPTIVES AND VENOUS TROMBOEMBULISM
Critical study, carried out after a careful re-reading of the scientific literature that observes that the increased risk of embolic venous thrombus events, results in a basic condition of oral contraception, dependent on the dose and duration of estrogen and instead independent of the progestin used.
Method of use and dosage
ARIANNA ® yellow coated tablets of 15 mcg of ethinyl estradiol and 60 mcg of gestodene, white tablets without active ingredients:
the particular formulation of the tablets contained in the pack allows the intake of one tablet a day without periods of suspension.
More precisely, in order to avoid forgetfulness or variations of the normal dosing schedule, the pharmaceutical company in question has experimented with a new therapeutic approach, consisting of:
- 24 consecutive days of taking a straw-yellow tablet (containing hormones);
- 4 consecutive days of taking a bank tablet (placebo).
Once the package is finished, without any suspension periods, it is necessary to start immediately with a new cycle.
Generally suspension hemorrhage appears about 2 days after taking the last yellow tablet, ie from the last intake of ethinyl estradiol and gestodene.
Variations in the dosing schedule could be necessary in particular conditions such as: recent abortions or pregnancies, previous contraceptive therapies and disorders of various nature.
ARIANNA ® warnings - Contraceptive Pill
Before undertaking oral contraceptives such as ARIANNA ®, the consultation of a specialist doctor is necessary, useful for evaluating both the therapeutic appropriateness and the absence of conditions incompatible with the administration of this drug.
Given the potential side effects of the cardiovascular system and other systems, related to the use of oral contraceptives, the presence of cardiovascular and neoplastic diseases in place or past, liver and kidney diseases, neurological and psychiatric disorders, metabolic pathologies such as diabetes and risk factors for cardiovascular diseases such as obesity or smoking, may be completely incompatible with oral hormone-based contraception.
If instead the specialist decides on the feasibility of oral contraception, it is necessary that the patient is subjected to periodic monitoring and informed of the potential risks and signs useful for recognizing the morbid states, so as to provide for the immediate suspension of therapy.
ARIANNA ® contains lactose so that its intake in patients with lactase enzyme deficiency, glucose / galactose malabsorption or lactose intolerance, could be associated with severe gastrointestinal disorders.
PREGNANCY AND BREASTFEEDING
ARIANNA ® is contraindicated in pregnancy and lactation due to the absence of studies able to characterize the safety profile of this drug, and given the ability of the two active ingredients contained in it to permeate the breast filter and concentrate in breast milk.
Interactions
The hepatic metabolism to which gestodene and ethinylestradiol are subjected, significantly increases the risk of clinically relevant drug interactions.
In fact the cytochromial enzymes responsible for the hepatic transformations of the aforementioned hormones are particularly susceptible to the inductive action of active ingredients such as rifampicin, phenytoin, barbiturates, antiretrovirals, antibiotics, herbal remedies such as St. John's wort, which increase the metabolism of 'ethinyl estradiol and gestodene, determine a reduction in blood concentrations and the consequent contraceptive effect.
In this regard, therefore, the simultaneous intake of more drugs must necessarily be preceded by a medical consultation, and possibly accompanied by contraceptive coverage systems.
ARIANNA ® Contraindications - Contraceptive Pill
ARIANNA ® is contraindicated in case of current or previous venous thrombosis, stroke, hypertension, metabolic pathologies such as diabetes mellitus, hypertension and dyslipidemia, liver and kidney function changes, malignant pathologies, neuro-psychiatric disorders, motor disorders, undiagnosed gynecological disorders and in case of hypersensitivity to the active ingredient or to one of its excipients.
Undesirable effects - Side effects
Although third-generation oral contraceptives were born with the aim of minimizing the side effects of oral contraception, taking ARIANNA ® has often been associated with adverse reactions such as mood disorders, irritability, headaches, dizziness, nausea, vomiting, abdominal pain, weight changes, increased breast tenderness and pain, haemorrhagic spotting and changes in cervical secretions.
However, there have been long-term but fortunately fewer side effects, such as cholestatic jaundice, erythema nodosum, pancreatitis and embolic arterial and venous thrombus.
Note
ARIANNA ® can be sold only under medical prescription.
